US Patent Number
8008092
Publication Date
8-30-2011
Abstract
Provided are methods and compositions for the treatment or prevention of ocular angiogenesis and neovascularization. Administration of inhibitors of the CCR3 receptor or its ligands eotaxin (CCL11), eotaxin-2 (CCL24) or eotaxin-3 (CCL26) inhibits ocular angiogenesis.
Assignees
University of Kentucky Research Foundation, Lexington, KY (US)
Application Number
12/247,722
Filing Date
10/08/2008
Recommended Citation
Ambati, Jayakrishna, "CCR3 Inhibition for Ocular Angiogenesis and Macular Degeneration" (2011). Ophthalmology and Visual Science Faculty Patents. 1.
https://uknowledge.uky.edu/ophthalmology_patents/1
